Overview

Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer

Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with radiation therapy may kill more tumor cells. The best timing for radiation therapy and combination chemotherapy in treating limited stage small cell lung cancer is not yet known . PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy given at different times along with combination chemotherapy in treating patients with limited stage small cell lung cancer.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
London Lung Cancer Group
Treatments:
Cyclophosphamide
Doxorubicin
Etoposide
Liposomal doxorubicin
Vincristine
Criteria
DISEASE CHARACTERISTICS: Histologically confirmed limited stage small cell lung cancer
Limited disease defined as within the hemithorax, mediastinum, or ipsilateral
supraclavicular nodes No evidence of extensive disease (i.e., contralateral lung or
contralateral supraclavicular nodes) No metastatic disease Measurable or evaluable disease

PATIENT CHARACTERISTICS: Age: Under 75 Performance status: ECOG 0-3 Life expectancy: At
least 8 weeks Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3
Hepatic: Bilirubin no greater than 2 mg/dL Renal: Creatinine normal OR Creatinine clearance
greater than 50 mL/min OR Pentetic acid/ethylenediaminetetraacetic acid clearance greater
than 70 mL/min Cardiovascular: No myocardial infarction in the 3 months prior to diagnosis
No pericardial effusion Pulmonary: No pleural effusion seen on chest x-ray Pleural effusion
identified on CT allowed, if not visible on chest x-ray Other: No medical condition that
excludes the use of chemotherapy or thoracic irradiation Must be able to tolerate the
prescribed study radiotherapy No other malignant tumor for at least 3 years except
nonmelanoma skin cancer

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
chemotherapy No concurrent chemotherapy Endocrine therapy: Concurrent prednisone or other
corticosteroids for hypercalcemia allowed Radiotherapy: No prior radiotherapy Surgery: Not
specified